title: Treatment of intracerebral hemorrhage associated with new oral anticoagulant use: the neurologist's view.
abstract: Intracerebral hemorrhage (ICH) associated with the use of oral anticoagulants (OAC-ICH) results in particularly severe strokes. A key target for the treatment of OAC-ICH is rapid restoration of effective coagulation. In patients receiving vitamin K antagonists, hemostatic factors such as prothrombin complex concentrate (PCC), fresh frozen plasma, and recombinant activated factor VII, in addition to vitamin K, can be used for anticoagulation reversal. However, emergency management of ICH during treatment with the new direct OACs (NOACs) is a major challenge. In the absence of specific antidotes, PCCs are recommended for NOAC reversal, mainly based on preclinical data.
authors.affiliation: Department of Stroke Medicine, Charing Cross Hospital, Imperial College London, Fulham Palace Road, London W6 8RF, UK; Department of Neurology, University of Heidelberg, INF 400, Heidelberg 69120, Germany. Electronic address: roland.veltkamp@imperial.nhs.uk.
authors.forename: Roland
authors.initials: R
authors.lastname: Veltkamp
authors.affiliation: Department of Neurology, University of Heidelberg, INF 400, Heidelberg 69120, Germany.
authors.forename: Solveig
authors.initials: S
authors.lastname: Horstmann
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D019317:Evidence-Based Medicine; D006801:Humans; D012307:Risk Factors
chemical_list: D000925:Anticoagulants
keywords: Intracerebral hemorrhage; New oral anticoagulants; Oral anticoagulation; Warfarin